HDAC inhibitors have long been investigated for their potential to impede cancer progression by altering the epigenetic landscape of tumor cells. These compounds block histone deacetylases, enzymes that typically modify chromatin structure to suppress gene expression. Though promising in theory, HDAC inhibitors have faced clinical setbacks, largely attributed to dose-limiting toxicities that affect healthy tissues. The Salk research team, headed by Ronald Evans, PhD, set out to dissect the nuanced biological functions of entinostat within pancreatic cancer cells to overcome these obstacles.

The researchers embarked on a comprehensive analysis using both human and murine pancreatic cancer models, meticulously charting transcriptional changes triggered by entinostat treatment. Contrary to the classical view of HDACs as mere gene silencers, their work illuminated a paradoxical role where HDAC activity is essential to sustain the expression of genes responsible for DNA repair. This unanticipated finding reshapes our understanding of HDAC biology in the context of pancreatic cancer and offers new strategic avenues for intervention.

Central to their discovery was the observation that HDAC enzymes facilitate the recruitment and proper deployment of the cell’s transcriptional machinery to DNA repair gene loci. When entinostat inhibits HDACs, this transcriptional apparatus is redistributed, leading to the repression of repair genes. The resultant deficiency impairs the tumor cells’ capacity to mend DNA lesions effectively, heightening their susceptibility to agents that inflict DNA damage—a cornerstone of many existing chemotherapies and radiation therapies.

This mechanistic insight carries profound therapeutic implications. Pancreatic tumors notoriously exhibit robust DNA repair capabilities, which confer resistance to DNA-damaging treatments. By pharmacologically crippling this defense via entinostat-mediated HDAC inhibition, the Salk team demonstrated significantly increased tumor cell vulnerability. When used in combination with DNA-damaging agents, entinostat synergistically amplified treatment efficacy, heralding a potential paradigm shift in pancreatic cancer therapy.

Recognizing the clinical challenges posed by the systemic toxicity of HDAC inhibitors, the researchers went further to engineer a novel drug delivery platform. Collaborating with experts at MIT, they crafted bottlebrush-shaped nanoparticles capable of encapsulating entinostat and preferentially delivering it to tumor sites. These nanoparticles gradually release the drug, maintaining therapeutic concentrations within the tumor microenvironment while minimizing exposure and adverse effects in healthy tissues.

Preclinical evaluations of the nanoparticle-based entinostat delivery system yielded promising results. Treated mice exhibited potent anti-tumor responses with reduced toxicity profiles, underscoring the translational potential of this approach. This innovation may not only enhance the therapeutic index of entinostat but also pave the way for similar strategies with other existing drugs that are limited by systemic side effects.

The study’s findings extend beyond pancreatic cancer, as many malignancies rely on heightened DNA repair activity to evade therapeutic injury. By disrupting this fundamental survival mechanism, HDAC inhibitors could be harnessed more broadly to sensitize tumors to DNA-damaging interventions, potentially reshaping the treatment landscape for various resistant cancers.

Future research will focus on fine-tuning the nanoparticle carriers to optimize drug release kinetics and delivery precision. A particularly exciting avenue involves co-loading nanoparticles with both entinostat and DNA-damaging agents, ensuring simultaneous local administration to maximize synergistic effects. Such innovations could markedly improve the efficacy and safety profile of combination therapies.

The work also exemplifies the critical importance of foundational research in elucidating the complexities of drug action and resistance. Rather than abandoning drugs with disappointing clinical outcomes, the study highlights how deep mechanistic understanding can unlock new therapeutic potentials, ultimately benefiting patients.

This research was made possible through numerous collaborations and generous funding, including support from the National Institutes of Health, various private foundations, and the Lustgarten Foundation. The collective efforts of interdisciplinary teams at the Salk Institute, MIT, UC San Diego, Dartmouth College, and beyond underscore the value of cooperative scientific inquiry.

As the Salk Institute continues its mission to pioneer transformative biological studies, these advances in pancreatic cancer treatment represent a beacon of hope. By marrying epigenetic therapeutics with innovative drug delivery systems, the prospect of more effective and tolerable cancer therapies moves closer to reality.

For clinicians and researchers alike, these insights offer a new lens through which to view HDAC inhibitors—not as flawed agents to be discarded but as powerful tools whose potential can be unleashed through strategic combinations and precision delivery technologies.

Subject of Research: Pancreatic cancer treatment; HDAC inhibition; epigenetic regulation of DNA repair; nanoparticle drug delivery

Article Title: HDAC inhibition sensitizes pancreatic tumors to DNA damage by global redistribution of the transcriptional machinery

News Publication Date: June 26, 2026

Web References: https://doi.org/10.1073/pnas.2536040123

References: Proceedings of the National Academy of Sciences, 2026

Image Credits: Salk Institute

Keywords: Pancreatic cancer, HDAC inhibitors, entinostat, DNA repair, transcriptional machinery, nanoparticle drug delivery, bottlebrush nanoparticles, chemotherapy sensitization, epigenetics, cancer therapeutics

Cancer remains one of the leading causes of death worldwide, with treatment modalities often hindered by tumor heterogeneity, systemic toxicity, and drug resistance. Against this challenging backdrop, scientists have long sought therapeutic vectors capable of localizing treatment within tumors while minimizing harm to healthy tissues. The probiotic strain EcN, naturally residing in the human gut and known for its safety profile, emerged as an ideal chassis for such interventions. Exploiting its inherent tumor-colonizing capability, the researchers genetically engineered EcN to produce Romidepsin (also known as FK228), a potent histone deacetylase inhibitor with established anticancer properties.

Romidepsin functions by modulating epigenetic regulation, thereby inducing cancer cell apoptosis and cell cycle arrest. Traditionally administered systemically with significant side effects, its localized biosynthesis within the tumor microenvironment by engineered EcN offers a highly targeted alternative. By integrating the biosynthetic pathway of Romidepsin into the bacterial genome, the modified EcN strain can autonomously synthesize and secrete this therapeutic compound upon colonizing tumor sites.

The team’s meticulous in vitro assays demonstrated robust production of Romidepsin by the engineered EcN under different culture conditions simulating the tumor microenvironment. Crucially, these bacteria maintained their viability and sustained drug synthesis without compromising their probiotic characteristics. Proceeding to in vivo studies, the researchers employed a murine model bearing orthotopic breast tumors. Upon intravenous administration, the engineered EcN selectively homed to the tumor tissue, effectively bypassing healthy organs and minimizing systemic exposure.

Within the tumor niche, the colonizing bacteria proliferated and delivered continuous localized doses of Romidepsin, leading to significant tumor growth inhibition compared to control groups receiving non-engineered bacteria or systemic chemotherapy. Histopathological analyses revealed increased tumor cell apoptosis and reduced proliferation markers, corroborating the dual action of EcN’s colonization and Romidepsin’s pharmacological effects.

This study’s implications extend beyond efficacy; it addresses critical safety concerns associated with bacteria-mediated therapies. The authors emphasize the need to develop strategies for controlled elimination of the therapeutic bacteria post-treatment to prevent potential adverse outcomes such as unintended infections or systemic dissemination. Future research directives include refining bacterial strains for optimized drug yield, engineering kill-switch mechanisms, and conducting rigorous toxicological assessments to transition from animal models to human clinical trials.

The innovative design exploits the symbiotic relationship between host and microbiota, highlighting the untapped potential of the human microbiome as a therapeutic platform. The dual-action mechanism of EcN combined with Romidepsin not only augments the therapeutic index but also leverages the natural tumor tropism of bacteria, minimizing off-target drug effects. This synergy exemplifies a novel biological engineering feat offering personalized, precision oncology solutions.

Experts in the field have hailed this proof-of-concept work as a significant stride toward biodegradable, self-sustaining cancer treatments that circumvent the pitfalls of conventional chemotherapy. The use of a broadly recognized probiotic bacterium also enhances translational feasibility, reducing regulatory barriers frequently posed by pathogenic bacterial vectors.

Despite these promising findings, the authors note the complexity of human tumor microenvironments and inter-patient variability as considerable challenges. Comprehensive studies elucidating EcN’s long-term colonization dynamics, immune interactions, and integration with existing therapeutic regimens are essential steps before clinical translation.

This pioneering investigation sets a precedent for designing multifunctional bacterial platforms that can be tailored to produce diverse small-molecule drugs, enabling an unprecedented modular approach to cancer therapy. By harnessing synthetic biology, researchers can now envision intricate microbial therapeutics capable of sensing, responding to, and remodeling tumor ecosystems in real time.

In conclusion, this study from Shandong University charts a bold new course in the field of bacteria-assisted tumor therapy, paving the way for revolutionary treatments that combine biological engineering with precision medicine. The potential to bio-manufacture potent anticancer agents within tumors themselves could revolutionize cancer care, decreasing systemic toxicity and improving patient outcomes.

With continued advancements, engineered probiotic strains like EcN may soon emerge as frontline weapons against cancer, signaling a paradigm shift that integrates microbiology, genetic engineering, and oncology into a cohesive therapeutic strategy. As the field eagerly anticipates human trials, this research represents a beacon of hope for millions battling malignancies worldwide.

Subject of Research: Animals

Article Title: Engineered romidepsin biosynthetic pathways in Escherichia coli Nissle 1917 improve the efficacy of bacteria-mediated cancer therapy

News Publication Date: March 17, 2026

Web References:

• https://journals.plos.org/plosbiology/article?id=10.1371/journal.pbio.3003657
• http://dx.doi.org/10.1371/journal.pbio.3003657

References:
Ma C, Li G, Sun T, Tang X, Qiu T, Song J, et al. (2026) Engineered romidepsin biosynthetic pathways in Escherichia coli Nissle 1917 improve the efficacy of bacteria-mediated cancer therapy. PLoS Biol 24(3): e3003657.

Keywords:
Synthetic biology, Escherichia coli Nissle 1917, Romidepsin, FK228, cancer therapy, tumor-targeted delivery, bacterial cancer therapy, epigenetic modulation, histone deacetylase inhibitor, probiotic engineering, bacterial colonization, breast cancer model

Histone deacetylase inhibitors (HDACis) have garnered significant attention over the past decade for their ability to alter gene expression by modulating chromatin structure. By inhibiting HDAC enzymes, these agents promote the accumulation of acetylated histones, resulting in transcriptional activation of tumor suppressor genes and induction of programmed cell death pathways in malignant cells. Abexinostat is distinguished by its pan-HDAC inhibitory activity, targeting multiple HDAC isoforms, which may enhance its antitumor efficacy across various lymphoma subtypes.

In the recently published Phase 1 trial executed between April 2020 and November 2023, twelve Chinese patients diagnosed with relapsed or refractory B cell NHL were enrolled. The cohort comprised individuals with follicular lymphoma (FL), diffuse large B cell lymphoma (DLBCL), and mantle cell lymphoma (MCL). The study’s primary goal was to evaluate safety and pharmacokinetic parameters of escalating oral doses of abexinostat administered twice daily in a regimen described as “one week on, one week off.” This intermittent schedule was designed to maximize antitumor activity while mitigating potential toxicities.

Patients received abexinostat at dose levels of 40 mg, 60 mg, and 80 mg twice daily, separated by a 4-hour interval, over seven days followed by a seven-day drug-free interval. Importantly, a single dose of abexinostat was administered three days prior to the initiation of the continuous dosing period to assess immediate pharmacokinetics and identify any dose-limiting toxicities. This strategic dosing approach enabled careful monitoring of tolerability while capturing pharmacologic data critical for optimizing future dosing regimens.

The safety evaluation revealed a highly tolerable profile of abexinostat across all dose levels. Notably, no dose-limiting toxicities were observed, even at the highest dose of 80 mg twice daily, which was subsequently declared the recommended Phase 2 dose (RP2D). Adverse events were predominantly mild to moderate, with the most common Grade 3 adverse events including thrombocytopenia and hypertriglyceridemia occurring in a minority of patients. These findings suggested that abexinostat could be administered safely at doses likely to produce meaningful biological effects.

Pharmacokinetic analyses underscored the drug’s favorable absorption and elimination characteristics. Median time to maximum plasma concentration (Tmax) ranged from 0.5 to 1.0 hours post-dose, indicating rapid systemic availability. The terminal half-life (T1/2) varied between 2.56 to 8.31 hours, supporting the twice-daily dosing strategy. Furthermore, plasma concentrations demonstrated dose-proportional kinetics, a desirable pharmacological attribute that facilitates predictable exposure-response relationships.

Efficacy signals from this early-phase trial were equally promising. Within the evaluable patient population, the objective response rate (ORR) was 40%, comprising one complete response and three partial responses. Particularly compelling was the 50% ORR observed among follicular lymphoma patients, a group traditionally characterized by chronic disease courses but often limited treatment responsiveness after multiple relapses. Median progression-free survival for follicular lymphoma patients reached 8.38 months, while duration of response extended to 7.82 months, durations encouraging for such a treatment-refractory population.

While overall survival data remain immature given the study’s timeframe, the absence of deaths during the observation period reinforces the favorable risk-benefit profile of abexinostat. The trial’s pioneering status as the first evaluation of this agent in a Chinese NHL population also expands understanding of HDAC inhibitor pharmacology across diverse ethnic groups, addressing an important gap in global oncology research.

The investigators concluded that the “one week on, one week off” oral dosing schedule is a rational approach based on pharmacokinetic observations, balancing steady drug exposure with recovery periods to reduce cumulative toxicity. This intermittent dosage regimen aligns with contemporary trends in targeted cancer therapies that seek to maintain efficacy while optimizing patient quality of life.

Beyond mere tolerability and pharmacokinetics, the demonstration of clear antitumor activity in heavily pretreated patients positions abexinostat as a candidate for further clinical development. Larger Phase 2 and 3 trials are warranted to confirm these early efficacy signals, delineate patient subgroups most likely to benefit, and potentially explore combination strategies with immunotherapies or standard chemotherapy agents.

This study contributes to the evolving landscape of precision oncology, where molecularly targeted agents such as HDAC inhibitors challenge traditional cytotoxic chemotherapy paradigms. In relapsed or refractory lymphomas, where therapeutic resistance diminishes options, new drugs with novel mechanisms of action are critical to improving survival and quality of life.

Moreover, the research underscores the importance of integrating pharmacokinetic assessments early in drug development programs. Understanding how a candidate drug behaves systemically in various patient populations informs safer and more effective dosing protocols, ultimately accelerating the pathway from bench to bedside.

As abexinostat advances through clinical stages, attention will also turn to biomarker identification to predict response and monitor treatment effects. Delineating epigenetic signatures or immune milieu alterations induced by HDAC inhibition could refine patient selection and personalize therapy.

The promising results from this Phase 1 trial offer hope to patients confronting the challenges of relapsed or refractory B cell NHL. In a disease domain in urgent need of innovation, abexinostat’s favorable safety and preliminary efficacy data propel it forward as a potential new weapon in the oncologist’s armamentarium.

Looking ahead, collaborative global efforts and comprehensive clinical investigations remain essential to validate these findings. Success in these endeavors could herald a new chapter in lymphoma treatment, harnessing epigenetic modulation to achieve durable remissions and improve patient outcomes worldwide.

Subject of Research: Abexinostat as a novel pan-histone deacetylase inhibitor in relapsed/refractory B cell non-Hodgkin lymphoma

Article Title: Safety, pharmacokinetics, and efficacy of abexinostat, an novel histone deacetylase inhibitor, in Chinese patients with relapsed/refractory B cell non-Hodgkin lymphoma: a Phase 1 study

Article References: Gui, L., Xie, Z., Qin, Y. et al. Safety, pharmacokinetics, and efficacy of abexinostat, an novel histone deacetylase inhibitor, in Chinese patients with relapsed/refractory B cell non-Hodgkin lymphoma: a Phase 1 study. BMC Cancer 25, 967 (2025). https://doi.org/10.1186/s12885-025-14370-y

Image Credits: Scienmag.com

DOI: https://doi.org/10.1186/s12885-025-14370-y